TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8072050
Drug: Both high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both high-dose and low-dose methadone
Study: 2468872
Drug: Nitrendipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (20 mg single oral daily dose for a 3‐week treatment period)
Study: 31519680
Drug: Enhanced community
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced community case management (CCM) plus monthly screening and treatment (MSAT) using rapid diagnostic tests (RDTs)
Study: 31519680
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care plus enhanced CCM, comprising active weekly screening for fever and detection and treatment of infections in fever positive individuals using RDTs
Study: 20006254
Drug: Group S7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group S7.5 (1.5 mL of 0.5% hyperbaric bupivacaine)
Study: 20006254
Drug: Group S5
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group S5 (1.0 mL of 0.5% hyperbaric bupivacaine)
Study: 20006254
Drug: Group S4
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group S4 (0.8 mL of 0.5% hyperbaric bupivacaine)
Study: 9751631
Drug: High-dose cytarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytarabine (3 g/m2)
Study: 9751631
Drug: Low-dose cytarabine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cytarabine (100 mg/m2)
Study: 9751631
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of cytarabine
Study: 20798194
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa (10,000 IU 3 times weekly)
Study: 18756431
Drug: 17alpha-hydroxyprogesterone caproate
Normalized name: 17alpha-Hydroxyprogesterone hexanoate
DrugBank: Hydroxyprogesterone caproate (DB06789)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 17alpha-hydroxyprogesterone caproate (17P), 341 mg intramuscularly, twice a week until 36 weeks
Study: 10925686
Drug: HCFU 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCFU 100 mg
Study: 8893355
Drug: Constant inflow
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant inflow (CFlow) administration
Study: 8893355
Drug: Constant fraction
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant fraction (CF) administration
Study: 2431395
Drug: Thymostimulin (TP‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymostimulin (TP‐1 Serono: 1.5 mg/kg/die for five days)
Study: 22539584
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose challenge (75-g glucose tolerance test)
Study: 17907110
Drug: Tesaglitazar (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tesaglitazar (0.5 or 1 mg/day)
Study: 10616948
Drug: Right Unilateral
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Right Unilateral ECT (RUL) with fixed high dose (378 mC)
Study: 10616948
Drug: Bifrontal ECT
Normalized name: Bos taurus frontal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifrontal ECT (BF) with age-based dosing
Study: 10616948
Drug: Dose-titration method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-titration method
Study: 9967
Drug: Medazepam (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medazepam (15 mg)
Study: 28719592
Drug: TL quadruple
Normalized name: TL-895
DrugBank: TL-895 (DB16471)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TL quadruple therapy (esomeprazole 40 mg b.d., bismuth 120 mg q.d.s., tetracycline 500 mg q.d.s., and levofloxacin 500 mg o.d.)
Study: 28719592
Drug: AL triple
Normalized name: BACITRACIN ZINC 400 [USP'U] in 1 g / NEOMYCIN SULFATE 0.0035 g in 1 g / POLYMYXIN B SULFATE 5000 [USP'U] in 1 g TOPICAL OINTMENT [PROHEAL TRIPLE ANTIBIOTIC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL triple therapy (esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., and levofloxacin 500 mg o.d.)
Study: 28719592
Drug: TL quadruple
Normalized name: TL-895
DrugBank: TL-895 (DB16471)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TL quadruple therapy
Study: 28719592
Drug: AL triple
Normalized name: BACITRACIN ZINC 400 [USP'U] in 1 g / NEOMYCIN SULFATE 0.0035 g in 1 g / POLYMYXIN B SULFATE 5000 [USP'U] in 1 g TOPICAL OINTMENT [PROHEAL TRIPLE ANTIBIOTIC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL triple therapy
Study: 25315022
Drug: LED therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: LED therapy (625 nm, 4 J/cm²) with Unna's boot
Study: 25315022
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment with Unna's boot (Control)
Study: 16816054
Drug: 0.625 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg/d of conjugated estrogens (n = 20)
Study: 16816054
Drug: Gabapentin titrated
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin titrated to 2,400 mg/d (n = 20)
Study: 10702891
Drug: Cilostazol with
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cilostazol with aspirin
Study: 8753934
Drug: Caffeine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (3 mg/kg body weight)
Study: 6211147
Drug: Heat‐killed sonicated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat‐killed sonicated suspension of malassezia ovalis
Study: 6211147
Drug: Heat‐killed sonicated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat‐killed sonicated suspension of Staphylococcus epidermidis
Study: 29850709
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control (325 mL twice per day for 12 weeks)
Study: 22828021
Drug: Preventive antiemetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive antiemetic medication
Study: 15983321
Drug: Irbesartan (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (150 mg/day)
Study: 29420324
Drug: Preoperative mitomycin
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative mitomycin C (MMC) injection (0.1 mL of 0.15 mg/mL MMC) followed by pterygium excision and conjunctival autograft (CAG)
Study: 24731467
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein containing 70 mg isoflavone daily for one year
Study: 21962771
Drug: Oral intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral intervention (O)
Study: 14719287
Drug: Bufei Keli
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bufei Keli (Chinese drug granules for invigorating the lung)
Study: 8658373
Drug: Thiorphan 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiorphan 1 mg (in 2 ml) followed by ANP 5 mg
Study: 8658373
Drug: Placebo (saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline) followed by ANP 5 mg
Study: 6459776
Drug: Salbutamol 5
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol 5 mg
Study: 22964703
Drug: Dexpantenolo (pantothenic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexpantenolo (pantothenic acid derivative), administered intravenously during the second and third post-operative day.
Study: 22964703
Drug: Spinal anesthetic
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anesthetic treatment group.
Study: 22964703
Drug: Peridural anesthetic
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peridural anesthetic treatment group.
Study: 15827560
Drug: CLA (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLA (2 g CLA)
Study: 15827560
Drug: Linoleic acid
Normalized name: Linoleic acid
DrugBank: Linoleic acid (DB14104)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linoleic acid (2 g linoleic acid)
Study: 12107508
Drug: Intravenous timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous timolol (0.2 mg)
Study: 12107508
Drug: Ocular timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ocular timolol (0.2 mg)
Study: 12107508
Drug: Ophthalmic timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic timolol
Study: 3898795
Drug: Intravenous timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous timolol
Study: 7697521
Drug: Francisella tularensis
Normalized name: Francisella tularensis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Francisella tularensis live vaccine strain (LVS)
Study: 2653095
Drug: Epidural fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural fentanyl (100 micrograms in saline 10 ml)
Study: 25778541
Drug: Grape/blueberry juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grape/blueberry juice (841 mg ACN/litre)
Study: 25778541
Drug: Grape/blueberry smoothie
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grape/blueberry smoothie (983 mg ACN/litre)
Study: 25778541
Drug: In vitro
Normalized name: glucuronidase in vitro test
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vitro absorption of grape/blueberry extract
Study: 24337060
Drug: Online version
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Online version of the FSFI (G-pp/ol after 15 days)
Study: 24337060
Drug: Traditional pen
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional pen and paper version of the FSFI (G-ol/pp after 15 days)
Study: 18753292
Drug: Terlipressin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin (2 mg infusion)
Study: 10917403
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg FLX daily
Study: 10917403
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg FLX weekly
Study: 1626677
Drug: Low-dose morphine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose morphine combined with bupivacaine for intercostal nerve blocks
Study: 15236812
Drug: Disulfiram treatment
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Disulfiram treatment
Study: 31793645
Drug: Syrup (alternative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syrup (alternative supplement for children)
Study: 31793645
Drug: Any supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any supplement (general outcome)
Study: 22609816
Drug: Sertindole (modal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertindole (modal dose 16 mg/day)
Study: 8083103
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further treatment (control group)
Study: 2287773
Drug: Once-a-day amikacin
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Once-a-day amikacin (14 mg/kg per day)
Study: 2287773
Drug: Once-a-day netilmicin
Normalized name: netilmicin
DrugBank: Netilmicin (DB00955)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once-a-day netilmicin (6.6 mg/kg per day)
Study: 6795047
Drug: 1,25-dihydroxycholecalciferol (1,25(OH)2D3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,25-dihydroxycholecalciferol (1,25(OH)2D3) alone in a daily dose of 0.25 micrograms
Study: 29893798
Drug: Fidaxomicin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fidaxomicin (200 mg once daily)
Study: 28487415
Drug: Standard therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapeutic pharmaceutical protocols (Control)
Study: 26377909
Drug: 40% dextrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40% dextrose gel (200 mg/kg)
Study: 23587733
Drug: teduglutide (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: teduglutide (0.05 mg/kg/day s.c.)
Study: 21863254
Drug: First eye
Normalized name: Medi-First Eyewash 98.3% Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: First eye surgery under topical anesthesia
Study: 21863254
Drug: Second eye
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second eye surgery under topical anesthesia
Study: 24067390
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive pill (OCP) users
Study: 7959185
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg atenolol (a selective beta 1 antagonist)
Study: 7959185
Drug: Matched dummy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched dummy tablets (control)
Study: 21741230
Drug: Lactobacillus brevis
Normalized name: Lactobacillus brevis
DrugBank: Lactobacillus brevis (DB18532)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus brevis CD2 lozenges
Study: 23644602
Drug: No L.
Approvals — FDA: no, EMA: no, PMDA: no
Description: No L. brevis lozenge (control)
Study: 23529727
Drug: GSK1322322 with
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1322322 with H2 blocker
Study: 19923796
Drug: GLY-230 (250,
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLY-230 (250, 500, or 750 mg daily for 14 days)
Study: 23242004
Drug: Rifampicin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin (600 mg once daily for 5 days)
Study: 8199751
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg pantoprazole
Study: 10235417
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg pantoprazole
Study: 8199751
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg pantoprazole
Study: 7977327
Drug: Nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10 mg orally)
Study: 21245882
Drug: Calcium fortified
Normalized name: Calcium fortified whole milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium fortified laddoo containing 405 mg calcium per day and a monthly vitamin D supplement of 30,000 IU
Study: 21245882
Drug: Non-fortified laddoo
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-fortified laddoo containing 156 mg of indigenous calcium and a monthly vitamin D supplement of 30,000 IU
Study: 16409195
Drug: House dust
Normalized name: House dust
DrugBank: House dust (DB10345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: House dust mite immunotherapy with Alutard SQ (Dermatophagoides pteronyssinus extract) for 52 weeks
Study: 12627930
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate 80 mg administered after consumption of a standardized continental breakfast
Study: 12627930
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate 80 mg administered during a fasting period
Study: 28198032
Drug: Metoclopramide (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (0.5 mg/kg, IV, three times a day)
Study: 28198032
Drug: Ondansetron (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (0.5 mg/kg, IV, three times a day)
Study: 23778412
Drug: Perindopril 4
Normalized name: perindopril 4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 4 mg daily
Study: 10229295
Drug: Hydrene (triamterene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrene (triamterene 50 mg with hydrochlorothiazide 25 mg) daily
Study: 1878335
Drug: Nicardipine 40
Normalized name: niCARdipine 40 mg/200 mL-D5% intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 40 mg slow-release b.i.d.
Study: 1878335
Drug: Nifedipine 20
Normalized name: nifedipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 20 mg slow-release b.i.d.
Study: 6130842
Drug: Quazepam 15
Normalized name: quazepam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quazepam 15 mg/night
Study: 27545509
Drug: Omega 3/6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega 3/6 capsules (three capsules twice daily)
Study: 27533157
Drug: Abaloparatide, 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abaloparatide, 80 μg
Study: 19452124
Drug: Calcium (500
Normalized name: calcium gluconate 45 mg calcium (500 mg) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (500 mg per day)
Study: 17465977
Drug: Alfentanil 0.5
Normalized name: alfentanil 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil 0.5 mg intravenously
Study: 15143082
Drug: VAC therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAC therapy (vincristine, dactinomycin, and cyclophosphamide)
Study: 15143082
Drug: VAC therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAC therapy with concomitant abdominal radiotherapy
Study: 11166149
Drug: Psychological Distress
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological Distress Inventory and Hospital Anxiety and Depression Scale administered before and during chemotherapy, and at the first follow‐up visit.
Study: 30181172
Drug: Adjuvant combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant combination chemotherapy
Study: 3349432
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tumor burden, histologic subtype, and sex
Study: 6439019
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin (NTG‐TTS), 5 mg/24 hr
Study: 31244356
Drug: Methotrexate +
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate + IFX therapy
Study: 28088187
Drug: Oral ergocalciferol
Normalized name: Ergocalciferol
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ergocalciferol plus calcitriol (n = 32)
Study: 28088187
Drug: Oral ergocalciferol
Normalized name: Ergocalciferol
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ergocalciferol plus placebo (n = 36)
Study: 21102493
Drug: Intravenous ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketorolac (60 mg) before surgery
Study: 19579920
Drug: 200 mcg
Normalized name: CrM 200 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mcg misoprostol placed in posterior fornix of case group
Study: 19579920
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet in control group
Study: 9924327
Drug: Dorzolamide/timolol combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzolamide/timolol combination solution administered twice daily (Cosopt)
Study: 9924327
Drug: Dorzolamide solution
Normalized name: dorzolamide Ophthalmic Solution
DrugBank: Dorzolamide (DB00869)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dorzolamide solution twice daily plus timolol maleate solution twice daily (concomitant)
Study: 9924327
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (combination and concomitant)
Study: 23462886
Drug: MSDC-0160 (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSDC-0160 (higher doses)
Study: 15963388
Drug: pioglitazone (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: pioglitazone (45 mg)
Study: 21672053
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose CYT003-QbG10
Study: 17458083
Drug: Corsodyl gel
Normalized name: chlorhexidine gluconate Oral Gel [Corsodyl]
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Corsodyl gel + surgical dressing
Study: 17458083
Drug: Corsodyl gel
Normalized name: chlorhexidine gluconate Oral Gel [Corsodyl]
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Corsodyl gel
Study: 12776809
Drug: SB-LOT (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB-LOT (30 mg coumarin and 180 mg troxerutin t.i.d.)
Study: 19637354
Drug: Dual-screen (annual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-screen (annual chest X-ray and 4-monthly sputum cytology)
Study: 12960598
Drug: Incremental nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incremental nitroglycerin infusion (NTG+Inf)
Study: 7567309
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V (25 mg/kg/day in 3 divided doses for 10 days)
Study: 7567309
Drug: Ceftibuten (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftibuten (9 mg/kg once daily for 10 days)
Study: 2174492
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of delta-9-tetrahydrocannabinol (THC) followed by 6.4 mg flumazenil
Study: 30773300
Drug: Decaffeinated group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decaffeinated group (150 mL decaffeinated coffee)
Study: 30773300
Drug: Caffeinated group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeinated group with CYP1A2 rs762551 CC genotype and daily caffeine consumption ≤90 mg/day
Study: 30773300
Drug: Caffeinated group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeinated group with CYP1A2 rs762551 AA/CA genotype and daily caffeine consumption ≤90 mg/day
Study: 20694295
Drug: Agaricus sylvaticus
Normalized name: AGARICUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agaricus sylvaticus (30 mg/kg/day)
Study: 16607096
Drug: Late initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Late initiation of hormone therapy (HT)
Study: 16607096
Drug: Late initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Late initiation of hormone therapy (HT) in women aged 60-69 years
Study: 10801247
Drug: Tangeretin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tangeretin (50 micromol/L)
Study: 10801247
Drug: Tangerine juice
Normalized name: TANGERINE JUICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tangerine juice (200 mL)
Study: 8664811
Drug: Treatment 1
Normalized name: CVS Acne Treatment 10% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment 1 (250 mg of standard vitamin C, 200 mg of vitamin E and 6 mg of beta‐carotene three times a day)
Study: 8664811
Drug: Treatment 2
Normalized name: epoch Blemish Treatment 2 % Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment 2 (150 mg of standard vitamin C, 500 mg of slow release vitamin C, 75 mg of vitamin E and 15 mg of beta‐carotene once a day)